ClinicalTrials.gg

Program

BMS-986521

A development code.

Its studies are led by Bristol-Myers Squibb.

Furthest: phase 1, since May 29, 20261 company-led study, 1 open or runningNext primary completion: Dec 27, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb11 open or runningphase 1since May 29, 2026May 29, 2026Dec 27, 2026phase 1 · NCT07655518
  • Named in Bristol-Myers Squibb’s own pipeline as BMS-986521, phase 1, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 29, 2026First study: phase 1 study in Healthy VolunteersFirst studyNCT07655518 · 12 planned · Belgium

Ahead

  1. Dec 27, 2026Primary completion: phase 1 study in Healthy VolunteersNCT07655518

TargetBeta

“A Phase 1, Open-label, Positron Emission Tomography (PET) Imaging Study to Evaluate M4 Muscarinic Acetylcholine Receptor Occupancy in the Central Nervous System Using [11C]MK-6884 PET Tracer Before and After Oral Administration of Multiple Doses of BMS-986521 in Healthy Adult Participants”study text, read by Claude · the study

Other programs on CHRM4

ProgramCompanyFurthest phaseStudies
GlycopyrrolateruleNovartisphase 487
xanomelineruleBristol-Myers Squibbphase 438
emraclidineAbbViephase 218
GXV-813Novartisphase 21
ABBV-1042AbbViephase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07655518Healthy Volunteers · Belgium1RecruitingDec 27, 202612

How it is read

Names in the registry

  • “BMS-986521”, 1 entry

Codes read as this program: BMS986521.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.